Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06528301
PHASE1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Sponsor: Umoja Biopharma

View on ClinicalTrials.gov

Summary

This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).

Official title: A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

106

Start Date

2025-03-10

Completion Date

2029-03

Last Updated

2026-01-12

Healthy Volunteers

No

Interventions

GENETIC

UB-VV111

UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.

DRUG

rapamycin

Rapamycin is an FDA-approved drug.

Locations (8)

City of Hope

Duarte, California, United States

The David and Etta Jonas Center for Cellular Therapy

Chicago, Illinois, United States

Washington University School of Medicine/Siteman Cancer Center

St Louis, Missouri, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

University of Cincinnatti Medical Center

Cincinnati, Ohio, United States

Fred Hutch Cancer Center

Seattle, Washington, United States

Royal North Shore Hospital

Saint Leonards, New South Wales, Australia

St. Vincent's Hospital Melbourne

Fitzroy, Victoria, Australia